A multicenter, randomized, controlled trial of rebamipide plus lansoprazole for the treatment of post-endoscopic submucosal dissection ulcers

Bin Yan; Zhongsheng Lu; Zhizheng Ge; Side Liu; Xuegang Guo; Dean Tian; Yuxiu Yang; Xiaobo Li; Wei Gong; Zhiguo Liu; Mei Liu; Bingxi Zhou; Kabing Zhao; Jing Yang; Yunsheng Yang

doi:10.18632/oncotarget.23127

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Withdrawal Notice

This paper was originally published in Oncotarget Advance Online Publications on 01/02/2018.
In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.

Clinical Research Papers:

A multicenter, randomized, controlled trial of rebamipide plus lansoprazole for the treatment of post-endoscopic submucosal dissection ulcers

Bin Yan, Zhongsheng Lu, Zhizheng Ge, Side Liu, Xuegang Guo, Dean Tian, Yuxiu Yang, Xiaobo Li, Wei Gong, Zhiguo Liu, Mei Liu, Bingxi Zhou, Kabing Zhao, Jing Yang and Yunsheng Yang _

Bin Yan1,*, Zhongsheng Lu1,*, Zhizheng Ge2, Side Liu3, Xuegang Guo4, Dean Tian5, Yuxiu Yang6, Xiaobo Li2, Wei Gong3, Zhiguo Liu4, Mei Liu5, Bingxi Zhou6, Kabing Zhao1, Jing Yang1 and Yunsheng Yang1

1Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing, China

2Department of Gastroenterology and Hepatology, Renji Hospital, Shanghai, China

3Department of Gastroenterology and Hepatology, Nanfang Hospital, Guangzhou, Guangdong Province, China

4Department of Gastroenterology and Hepatology, Xijing Hospital, Xian, Shanxi province, China

5Department of Gastroenterology and Hepatology, Tongji Hospital, Wuhan, Hubei province, China

6Department of Gastroenterology and Hepatology, Henan Provincial People’s Hospital, Zhengzhou, Henan Province, China

*These authors contributed equally to this work

Correspondence to:

Yunsheng Yang, email: [email protected]

Keywords: randomized clinical trial; endoscopic submucosal dissection; ulcer; lansoprazole; rebamipide

Received: September 29, 2017 Accepted: November 15, 2017 Published: January 02, 2018

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23127

Publication Alerts

Withdrawal Notice

Clinical Research Papers:

A multicenter, randomized, controlled trial of rebamipide plus lansoprazole for the treatment of post-endoscopic submucosal dissection ulcers